Zevenbergen Capital Investments LLC Invests $16.29 Million in TransMedics Group, Inc. $TMDX

Key Points

• Zevenbergen Capital Investments LLC has purchased a new stake in TransMedics Group, acquiring 121,528 shares valued at approximately $16.3 million, representing about 0.36% of the company.
• Recent analyst ratings have varied, with Canaccord Genuity lifting their target price to $142.00 and maintaining a "buy" rating, while Wall Street Zen downgraded the stock from "buy" to "hold."
• TransMedics Group reported earnings of $0.92 per share for the last quarter, significantly surpassing analysts' expectations of $0.48, with a revenue increase of 37.7% year-over-year.

Zevenbergen Capital Investments LLC acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 121,528 shares of the company's stock, valued at approximately $16,286,000. Zevenbergen Capital Investments LLC owned 0.36% of TransMedics Group as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in TransMedics Group by 244.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock worth $209,448,000 after purchasing an additional 2,209,996 shares during the period. Mackenzie Financial Corp grew its holdings in TransMedics Group by 73.0% in the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock worth $51,635,000 after purchasing an additional 349,403 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in TransMedics Group by 16.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock worth $56,307,000 after purchasing an additional 128,474 shares during the period. Capital Fund Management S.A. grew its holdings in TransMedics Group by 100.4% in the first quarter. Capital Fund Management S.A. now owns 252,294 shares of the company's stock worth $16,974,000 after purchasing an additional 126,414 shares during the period. Finally, GAMMA Investing LLC grew its holdings in TransMedics Group by 43,744.2% in the first quarter. GAMMA Investing LLC now owns 105,226 shares of the company's stock worth $7,080,000 after purchasing an additional 104,986 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Trading Up 2.1%

NASDAQ:TMDX traded up $2.53 during midday trading on Friday, reaching $123.63. 966,592 shares of the stock traded hands, compared to its average volume of 1,295,332. The company has a fifty day moving average of $115.61 and a 200 day moving average of $106.57. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $169.29. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The stock has a market capitalization of $4.21 billion, a P/E ratio of 64.24 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. During the same period in the prior year, the business earned $0.35 EPS. The company's revenue for the quarter was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. On average, research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Morgan Stanley raised their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Canaccord Genuity Group lifted their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. Oppenheimer raised their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research report on Tuesday, June 17th. Finally, Wall Street Zen lowered shares of TransMedics Group from a "buy" rating to a "hold" rating in a research report on Saturday, August 30th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $125.40.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.